anmeimutumab

Anmeimutumab (SYL101) is a humanized monoclonal antibody of the IgG1 kappa isotype that targets the epidermal growth factor receptor (EGFR). Developed by Shanghai Sylon Biotechnology, it is currently being evaluated in clinical trials for the treatment of various advanced solid tumors, including colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal cancer, and pancreatic cancer. Anmeimutumab works by binding to the extracellular domain of EGFR, thereby preventing the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α). This blockade inhibits the activation of the receptor's tyrosine kinase activity and subsequent downstream signaling through the RAS/MAPK and PI3K/AKT pathways, which are critical for tumor cell proliferation, survival, and metastasis. Additionally, as an IgG1 antibody, it may facilitate antibody-dependent cellular cytotoxicity (ADCC) against tumor cells overexpressing EGFR.

Other names

anmeimutamab